Treatment With Tumour Infiltrating Lymphocytes and Interleukin-2 in Patients With Metastatic Melanoma: A Pilot Study

Biotherapy
doi 10.1007/bf02172659
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Phase II Clinical Trial of Adoptive Cell Therapy for Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Biochemotherapy of Metastatic Malignant Melanoma. Predictive Value of Tumour-Infiltrating Lymphocytes

British Journal of Cancer
Cancer ResearchOncology
2001English

Neoepitope Targets of Tumour-Infiltrating Lymphocytes From Patients With Pancreatic Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Tumour Infiltrating Lymphocytes Correlate With Improved Survival in Patients With Esophageal Squamous Cell Carcinoma

Scientific Reports
Multidisciplinary
2017English

Minimally Invasive Liver Resection to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy in Patients With Metastatic Melanoma

World Journal of Surgical Oncology
SurgeryOncology
2012English

Tumor-Infiltrating Lymphocytes in Melanoma

Current Oncology Reports
Oncology
2012English

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

A Randomised Dose Escalation Study of Subcutaneous Interleukin 2 With and Without Levamisole in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
1996English

A Multi-Center Phase II Study of High Dose Interleukin-2 Sequenced With Vemurafenib in Patients With BRAF-V600 Mutation Positive Metastatic Melanoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy